secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001193125-24-195950
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q2 revenue $122.7M (+23% YoY); GAAP EPS $0.33, non-GAAP $0.56; guides upper end of $455-475M
--------------------------------------------------------------------------------

- Total Q2 2024 revenue $122.7M, up 23.3% YoY; FIRDAPSE $77.4M (+19.2%), FYCOMPA $36.5M (+5.7%), AGAMREE $8.7M (new launch).
- GAAP net income $40.8M ($0.33 diluted); non-GAAP net income $69.6M ($0.56 diluted), up 15.3% YoY.
- Cash and equivalents $375.7M at June 30, 2024, up from $137.6M at Dec 31, 2023 (+173%).
- Reaffirms 2024 total revenue guidance of $455-$475M; expects results in upper half of range.
- Announced license agreement for AGAMREE in Canada to expand rare orphan portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524195950/0001193125-24-195950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524195950/d873312d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-195950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer